Junod

Denosumab, the active ingredient in Junod, is a monoclonal antibody presented as a subcutaneous formulation for injection use. It treats osteoporosis in postmenopausal women, helps prevent skeletal‑related events in patients with bone metastases, and addresses bone loss associated with glucocorticoid therapy.

GNH USA supplies Junod as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Denosumab acts on the RANK‑L pathway to reduce bone resorption in several bone‑related conditions.

Postmenopausal osteoporosis: reduces the risk of vertebral, hip and non‑vertebral fractures. Bone metastases (skeletal‑related events): delays pathological fractures, spinal cord compression and the need for radiation or surgery. Glucocorticoid‑induced bone loss: helps maintain bone mineral density and lowers fracture risk.

Common Side Effects: - Injection site pain or erythema - Low blood calcium (hypocalcemia) - Musculoskeletal pain - Upper respiratory tract infection - Skin rash or itching

Serious or Rare Side Effects: - Osteonecrosis of the jaw (ONJ) - Atypical femur fracture - Severe hypersensitivity or anaphylaxis - Severe hypocalcemia requiring medical intervention - Serious infections such as cellulitis or pneumonia

Before initiating therapy, clinicians should assess calcium status, renal function and dental health.

Calcium/Vitamin D supplementation: ensure adequate intake before and during treatment. Renal impairment: evaluate renal function and serum calcium levels. Hypocalcemia risk: monitor calcium, especially in patients with vitamin D deficiency. Dental procedures: obtain dental evaluation prior to starting; avoid invasive procedures during therapy. Pregnancy and lactation: use only if potential benefit outweighs risk and after specialist consultation. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Denosumab may interact with several medicines that affect calcium balance or immune function.

Major Interactions (Avoid): - Bisphosphonates: concurrent use can increase hypocalcemia risk. - High‑dose corticosteroids or other immunosuppressants: may heighten infection susceptibility. - Live vaccines: contraindicated while receiving denosumab.

Moderate Interactions (Monitor Closely): - Calcium supplements: monitor for hypercalcemia if excessive. - Renal replacement therapy: adjust monitoring of calcium and phosphate. - Other anti‑resorptive agents: assess cumulative effect on bone turnover.